Effects of Prescription OMega-3 Fatty Acids (Omacor, Lovaza) on Platelet Activity in Patients With Coronary Artery Disease With Hypertriglyceridemia (OMPA-CAD).

Trial Profile

Effects of Prescription OMega-3 Fatty Acids (Omacor, Lovaza) on Platelet Activity in Patients With Coronary Artery Disease With Hypertriglyceridemia (OMPA-CAD).

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Omega-3-acid ethyl esters (Primary)
  • Indications Coronary artery disease; Hypertriglyceridaemia
  • Focus Pharmacodynamics
  • Acronyms OMPA-CAD
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jul 2011 Status changed from not yet recruiting to completed
    • 01 Jul 2011 EudraCT2009-018211-71 added as identifier
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top